Presidential Decree Enables Methylphenidate as Primary Treatment for ADHD in Maldives

President Dr Mohamed Muizzu has issued a decree amending the Drugs Act to allow the use of methylphenidate as a first-line treatment for Attention Deficit Hyperactivity Disorder (ADHD). The legislative change, published in the Government Gazette, takes effect immediately to improve healthcare access for those managing the developmental condition. The amendment follows a recommendation from the National Drug Control Council and subsequent deliberation by the Cabinet. After receiving Cabinet approval, the proposal was submitted to the Majlis (the Maldivian Parliament). During the 17th sitting of the first session on May 11, Parliament approved the removal of methylphenidate from the list of prohibited drugs under Schedule I of the Drugs Act. This regulatory shift establishes a legal framework that allows healthcare providers to prescribe methylphenidate to patients diagnosed with ADHD. By removing the drug from the prohibited list, the government aims to provide a critical medical tool for those who require pharmacological intervention alongside therapy. Medical experts recognize ADHD as one of the most prevalent developmental conditions in early childhood. Research indicates that combining methylphenidate with therapeutic interventions can substantially alleviate core symptoms, improving the quality of life for children and their families. Regulatory authorities have described the medication as an "essential and highly important treatment," emphasizing that the legislative change is a clinical imperative. The move reflects a commitment to aligning Maldivian pharmaceutical laws with international medical standards to ensure children with ADHD receive evidence-based care.